
Sign up to save your podcasts
Or


For many teams, particles and aggregates are treated as a late-stage compliance headache or a sudden fire drill during manufacturing. But what if we looked closer? Particle populations can actually reveal deep insights about your formulation stability, process robustness, and potential technology transfer risks long before you reach commercial scale.
In this episode of Life Science Solutions, host Chris Adkins sits down with Dr. Tim Menzen, Chief Technology Officer at Coriolis Pharma, a science-driven CRO specializing in formulation development and advanced analytics for biopharmaceuticals. With a PhD focused on the thermal unfolding and aggregation of monoclonal antibodies, Tim brings a wealth of expertise to the evolving landscape of biologic particles.
If your organization is looking to modernize how it approaches formulation and process development, this conversation is packed with cutting-edge insights.
Topics Include:
This episode is designed for CSV, CQV, and QA professionals who want a clearer, more efficient approach to validation, supported by real risk based thinking.
🎧 Subscribe to Life Science Solutions wherever you get your podcasts, and share this episode with your quality, validation, and IT teams!
📍 Recorded at Kymanox HQ in Research Triangle Park, North Carolina.
By KymanoxFor many teams, particles and aggregates are treated as a late-stage compliance headache or a sudden fire drill during manufacturing. But what if we looked closer? Particle populations can actually reveal deep insights about your formulation stability, process robustness, and potential technology transfer risks long before you reach commercial scale.
In this episode of Life Science Solutions, host Chris Adkins sits down with Dr. Tim Menzen, Chief Technology Officer at Coriolis Pharma, a science-driven CRO specializing in formulation development and advanced analytics for biopharmaceuticals. With a PhD focused on the thermal unfolding and aggregation of monoclonal antibodies, Tim brings a wealth of expertise to the evolving landscape of biologic particles.
If your organization is looking to modernize how it approaches formulation and process development, this conversation is packed with cutting-edge insights.
Topics Include:
This episode is designed for CSV, CQV, and QA professionals who want a clearer, more efficient approach to validation, supported by real risk based thinking.
🎧 Subscribe to Life Science Solutions wherever you get your podcasts, and share this episode with your quality, validation, and IT teams!
📍 Recorded at Kymanox HQ in Research Triangle Park, North Carolina.